Mikhail Blagosklonny Advocates Innovative Solutions To Cancer And Aging

Mikhail Blagosklonny recently took time to unwrap the power packed inside Rapamycin. He tells us it is in use in organ transplant procedures, as a therapy option for lung disease and in the management of cancer. It also goes by the names Sirolimus and Rapamune. Mikhail Blagosklonny has done groundbreaking research on therapy options available to cancer patients. He has also done extensive studies on the application of anti-aging therapies in the management of various conditions.Mikhail Blagosklonny believes Rapamycin is an effective strategy in cancer management. He works as a professor of oncology. He was attached to the Rosewell Park Cancer Institute. He also serves as the editor-in-chief of the medical peer-reviewed journal, Oncotarget. Besides the uses mentioned above, he asserts Rapamycin is also used in the treatment of renal failure, kidney disease, and rare lung disease. It has been proven to be friendly to the kidneys.Rapamycin is powerful in suppressing tumors as well as stimulating the body’s immune system to act against the tumors. In 2014, the drug was proven to enhance immunity in the elderly. It is an excellent cure for facial spots and rashes.

The drug is being tested to evaluate its effectiveness in slowing down aging and adding years to your life. Additionally, it is being proposed as a therapy option for Alzheimer’s, loss of muscle mass and lupus.Mikhail Blagosklonny is a prominent research scientist and philanthropist. He is driven by the fact that your risk of getting cancer increases, as you get older. He has made remarkable contributions in oncology. He is dedicated to building the teams to take the research to the next level. He inspires his peers and edits hundreds of their peer-reviewed papers and continues to train world-class scientists.He is passionate about sharing his research to enable scientists to discover effective therapy options quickly. He has mobilized significant support for cancer research through Oncotarget. The journal maximizes the impact of research through insightful accelerated peer review that makes papers available to a large audience quickly. The weekly journal recently upgraded to publishing two journals per week. This is in response to an increase in the value and volume of papers submitted by authors.

Besides oncology and aging, Mikhail Blagosklonny oversees the publication of research papers in numerous other disciplines. These include pathology, microbiology, neuroscience, cardiology and pharmacology among others. Mikhail Blagosklonny believes in delivering a non-invasive and affordable cure for cancer. He is studying ways to kill cancer cells while allowing healthy cells to continue normal growth. He is associated with numerous other publications in editorial positions. Some of these include Aging, Cancer Biology & Therapy as well as Cell Death & Differentiation.As a renowned scientist, he has authored more than 270 peer-reviewed studies distributed in several publications. He has previously worked for Ordway Research Institute. Mikhail Blagosklonny has also served the New York Medical College as an associate professor. He learned at the First Pavlov State Medical University of St. Petersburg where he graduated with a medical degree in internal medicine and later on a Ph.D. in the field of experimental medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *